August 31st, 2016 Xconomy National — Novartis has decided to dissolve its group that has been working on a cutting-edge therapy to treat cancer. In an internal email obtained by Endpoints , the head of the healthcare giant's cell and gene ... Xconomy, 1 month ago
A dispute involving Michael J. Fox Foundation might delay the most promising new treatment for Parkinson's disease weve seen in decades
Acrucial clinical trial of the most promising new treatment for Parkinson's disease in decades might be delayed because of a feud between a key scientist and the influential Michael J. Fox Foundation . The prominent foundation — the richest ...Business Insider, 1 month ago As Parkinson's patients wait, Fox Foundation and scientist feud over drug trial StatNews.com, 1 month ago
Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation As First-Line Treatment For HR+/HER2- Advanced Breast Cancer Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer ...BioSpace, 1 month ago Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer SPi World News, 1 month ago
on your WebpageAdd Widget >Get your members hooked!